| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
OP-5244 (OP5244) is a novel, orally bioavailable and potent CD73 inhibitor with cancer immunomodulatory effects. It inhibits CD73 with an IC50 of 0.25 nM. OP-5244 acts byreversing immunosuppressive environments via blocking of adenosine production.
| ln Vitro |
In H1568 (NSCLC) cells, OP-5244 suppresses the synthesis of adenosine (ADO) with an EC50 of 0.79±0.38 nM [1]. With an EC50 of 0.22 nM, OP-5244 prevents CD8+ T lymphocytes originating from peripheral blood from hydrolyzing AMP to ADO[1]. Op-5244 (4.1-1000 nM; 96 hours) restores the proliferation and cytokine production of CD8+ T cells that are suppressed by AMP [1]. ADO synthesis in human and murine cancer cell lines (H1568 and EMT6, respectively) is totally inhibited by OP-5244 (0.01 nM-10 μM) [1].
|
|---|---|
| ln Vivo |
Tumor growth inhibition in mice indicates that OP-5244 (15 mg/kg/day; subcutaneously for 13 days) has anti-tumor effects when used alone [1]. In mice, OP-5244 (150 mg/kg; orally administered twice daily for 16 days) reverses immunosuppression and enhances CD8+ T cell infiltration [1]. OP-5244 (0.2 mg/kg; intravenous) has low steady-state volume of distribution (rat 0.22, dog 0.29, crab-eating monkey 0.10 L/kg/h) and moderate plasma clearance (rat 0.18, dog 1.22, macaque 0.05 L/kg/h)[1]. AUC (rat 1.96, dog 1.75, cynomolgus monkey 14.2 μM?h) and Cmax (rat 0.82, dog 1.25, cynomolgus monkey 1.72 μM) are seen with OP-5244 (10 mg/kg; oral) [1].
|
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse with breast cancer[1]
Doses: 15 mg/kg/day Route of Administration: Sc for 13 days Experimental Results: Inhibited tumor growth. demonstrated a 95% lower ADO/AMP ratio compared to that of the vehicle group. |
| References |
| Molecular Formula |
C19H29CLN5O9P
|
|---|---|
| Molecular Weight |
537.8884
|
| Exact Mass |
535.159
|
| CAS # |
2381268-71-7
|
| Related CAS # |
OP-5244 sodium
|
| PubChem CID |
154585769
|
| Appearance |
White to pink solid powder
|
| LogP |
-1.6
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
764
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
ClC1=NC(=C2C([H])=NN(C2=N1)[C@@]1([H])[C@@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[C@@](C([H])([H])O[H])(C([H])([H])OC([H])([H])[H])P(=O)(O[H])O[H])O1)O[H])O[H])N([H])C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]
|
| InChi Key |
MVKIUWCYHMQOCI-VVZOVNLRSA-N
|
| InChi Code |
InChI=1S/C20H31ClN5O8P/c1-33-10-20(9-27,35(30,31)32)7-6-13-14(28)15(29)18(34-13)26-17-12(8-22-26)16(24-19(21)25-17)23-11-4-2-3-5-11/h8,11,13-15,18,27-29H,2-7,9-10H2,1H3,(H,23,24,25)(H2,30,31,32)/t13-,14-,15-,18-,20-/m1/s1
|
| Chemical Name |
((R)-4-((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-1-hydroxy-2-(methoxymethyl)butan-2-yl)phosphonic acid
|
| Synonyms |
OP5244 OP 5244 OP-5244
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~464.78 mM)
H2O : ~100 mg/mL (~185.91 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.5 mg/mL (12.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 65.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.5 mg/mL (12.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 65.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 6.5 mg/mL (12.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8591 mL | 9.2956 mL | 18.5912 mL | |
| 5 mM | 0.3718 mL | 1.8591 mL | 3.7182 mL | |
| 10 mM | 0.1859 mL | 0.9296 mL | 1.8591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
